Sonnet Biotherapeutics Holdings Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Sonnet Biotherapeutics Holdings Inc (SONN) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Sonnet Biotherapeutics Holdings Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 0M vs 271,067M combined for tracked competitors (0.0% combined share).
- Peer differentiation: Revenue per employee of $0.04M compares with $0.94M for the peer group (0.0x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
Sonnet Biotherapeutics Holdings Inc vs. its Competitors, Q4 2025
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Sonnet Biotherapeutics Holdings Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Sonnet Biotherapeutics Holdings Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (6) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Sonnet Biotherapeutics Holdings Inc's competitor groups requires a Commercial License.
Sonnet Biotherapeutics Holdings Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Sonnet Biotherapeutics Holdings Inc | - | - | - | Yes |
| Competitors combined (78) | ||||
| High-Confidence Competitors (6) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
SONN Stock Performance relative to its Competitors
SONN Stock Performance relative to High-Confidence Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Adlai Nortye Ltd | 282.9% | Outperformed |
| 2 | Iovance Biotherapeutics inc | 282.9% | Outperformed |
| 3 | Nurix Therapeutics Inc | 282.9% | Outperformed |
| 4 | Enliven Therapeutics Inc | 282.9% | Outperformed |
| 5 | Palvella Therapeutics Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Sonnet Biotherapeutics Holdings Inc's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Publicly Traded Peers of Sonnet Biotherapeutics Holdings Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Sonnet Biotherapeutics Holdings Inc | 5.20 | 0.35 |
| Novartis Ag | 287,150.40 | 56,674.00 |
| Astrazeneca Plc | 259,526.30 | 58,739.00 |
| Amgen Inc | 227,462.72 | 38,095.00 |
| Pfizer Inc | 163,675.28 | 63,696.00 |
| Bristol myers Squibb Company | 130,826.24 | 49,186.00 |
| SUBTOTAL | 1,167,767.40 | 271,429.81 |
Sign in to see all competitors of Sonnet Biotherapeutics Holdings Inc .
Sources: Sonnet Biotherapeutics Holdings Inc's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Sonnet Biotherapeutics Holdings Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Sonnet Biotherapeutics Holdings Inc's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Novartis | Named by the company | 85% |
| Amgen | Named by the company | 85% |
| Pfizer | Named by the company | 85% |
| Bristol-Myers Squibb | Named by the company | 85% |
| Xoma Royalty Corporation | Named by the company | 85% |
| Merck | Named by the company | 85% |
| AstraZeneca/MedImmune | Named by the company | 85% |
| Roche/Genentech | Named by the company | 85% |
| Precigen Inc | Named by the company | 85% |
| Xilio Therapeutics Inc | Named by the company | 85% |
| Krystal Biotech Inc | Named by the company | 85% |
| Astrazeneca Plc | Named by the company | 85% |
| Werewolf Therapeutics Inc | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Sonnet Biotherapeutics Holdings Inc's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.
Sonnet Biotherapeutics Holdings Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Sonnet Biotherapeutics Holdings Inc | 5 | 38,883 | -1,779,054 |
| Novartis Ag | 287,150 | 752,973 | 185,566 |
| Astrazeneca Plc | 259,526 | 706,847 | 123,141 |
| Amgen Inc | 227,463 | 2,930,385 | 672,538 |
| Pfizer Inc | 163,675 | 849,280 | 58,267 |
| Bristol myers Squibb Company | 130,826 | 1,513,415 | 285,354 |
| PEERS TOTAL | 1,167,762 | 944,842 | 150,626 |
Sign in to see all peers for Sonnet Biotherapeutics Holdings Inc .
Sonnet Biotherapeutics Holdings Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent filing. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Pfizer Inc | United States 58.91 % |
| Bristol myers Squibb Company | United States 67.79 % |
| Hutchmed china Limited | CN 74.28 % |
| Krystal Biotech Inc | United States 75.19 % |
| Iovance Biotherapeutics inc | US 98.66 % |
Source: revenue geography as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Sign in to see all peers for Sonnet Biotherapeutics Holdings Inc .
Sonnet Biotherapeutics Holdings Inc's Business Segment Mix vs Peers
Revenue by operating segment, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Amgen Inc | Reportable 100.00 % |
| Pfizer Inc | U.S. Commercial Division 52.92 % |
| Madrigal Pharmaceuticals Inc | Reportable 100.00 % |
| Hutchmed china Limited | Other Ventures segment 47.94 % |
| Rhythm Pharmaceuticals Inc | Single Reportable 100.00 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Sonnet Biotherapeutics Holdings Inc .
Sonnet Biotherapeutics Holdings Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 498 companies in Sonnet Biotherapeutics Holdings Inc's industry classification, broader than the peer set above. Market cap in millions of $.Sonnet Biotherapeutics Holdings Inc ranks #0 of 498 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 827, indicating a unconcentrated market structure (U.S. antitrust guidance: below 1,500 unconcentrated, 1,500 to 2,500 moderately concentrated, above 2,500 highly concentrated).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Eli Lilly And Company | 1,062,533 | 19.39 % |
| 2 | Johnson and Johnson | 664,610 | 12.13 % |
| 3 | Beone Medicines Ltd | 545,679 | 9.96 % |
| 4 | Abbvie Inc | 467,633 | 8.54 % |
| 5 | Merck and Co Inc | 1,234 | 5.2% |
| 6 | Novartis Ag | 1,234 | 5.2% |
| 7 | Abbott Laboratories | 1,234 | 5.2% |
| 8 | Novo Nordisk A | 1,234 | 5.2% |
| 9 | Pfizer Inc | 1,234 | 5.2% |
| 10 | Vertex Pharmaceuticals Inc | 1,234 | 5.2% |
| 0 | Sonnet Biotherapeutics Holdings Inc | 5 | 0.00 % |
Market cap and industry share for the rest of Sonnet Biotherapeutics Holdings Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2025-12-02.
Sonnet Biotherapeutics Holdings Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in SEC filings.| Metric | 2014 | 2015 | 2016 | 2017 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | 178.84 % | 168.95 % | -1.64 % | -0.65 % | 201.57 % | - | - | - |
| Operating Margin | -13.58 % | -27.10 % | -6.28 % | -12.64 % | -53.34 % | - | - | -11,292.51 % |
| Return on Invested Capital | -12.37 % | -23.18 % | -7.15 % | -16.61 % | -51.49 % | -783.75 % | - | -1,648.13 % |
| P/E | - | - | - | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Sonnet Biotherapeutics Holdings Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 827 (see Industry Market Structure & Concentration above) |
| Supplier Power | Not covered on this page | See Sonnet Biotherapeutics Holdings Inc's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See Sonnet Biotherapeutics Holdings Inc's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
Sonnet Biotherapeutics Holdings Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) — not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
No rule matched.
Weaknesses
- Return on equity 853.5 points below the industry aggregate.
- Underperforming the U.S.A. 500 over the trailing 12 months.
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
- A meaningful share of tracked competitors (46.10 %) show financial-distress signals, a possible opening to gain share.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-41.9% annualized).
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Sonnet Biotherapeutics Holdings Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Sonnet Biotherapeutics Holdings Inc | 0.49 | 1.35 | - |
| Novartis Ag | 0.42 | 1.12 | 0.02 |
| Astrazeneca Plc | 0.19 | 0.94 | 0.51 |
| Amgen Inc | 0.46 | 1.26 | 5.86 |
| Pfizer Inc | 0.04 | 1.24 | 0.71 |
| Bristol myers Squibb Company | 0.49 | 1.35 | 2.31 |
Sign in to see all peers for Sonnet Biotherapeutics Holdings Inc .
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Sonnet Biotherapeutics Holdings Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Sonnet Biotherapeutics Holdings Inc | Q3 2025 | - | - |
| Novartis Ag | Q4 2025 | +9.6 % | +17.0 % |
| Astrazeneca Plc | Q4 2025 | +8.6 % | +45.3 % |
| Amgen Inc | Q2 2026 | +9.5 % | +65.9 % |
| Pfizer Inc | Q2 2026 | +2.6 % | - |
| Bristol myers Squibb Company | Q2 2026 | +5.7 % | +152.6 % |
| PEERS TOTAL | +8.3 % | +29.1 % |
Sign in to see all peers for Sonnet Biotherapeutics Holdings Inc .
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Sonnet Biotherapeutics Holdings Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Sonnet Biotherapeutics Holdings Inc | Q3 2025 | - | - |
| Novartis Ag | Q4 2025 | +18.3 % | +13.3 % |
| Astrazeneca Plc | Q4 2025 | +11.2 % | +46.0 % |
| Amgen Inc | Q2 2026 | -6.6 % | +39.0 % |
| Pfizer Inc | Q2 2026 | +8.3 % | -13.8 % |
| Bristol myers Squibb Company | Q2 2026 | +10.5 % | -15.5 % |
Sign in to see all peers for Sonnet Biotherapeutics Holdings Inc .
Sonnet Biotherapeutics Holdings Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Sonnet Biotherapeutics Holdings Inc | - | - | - |
| Novartis Ag | 12.59% | 12.62% | 30.00% |
| Astrazeneca Plc | 8.97% | 19.67% | 21.00% |
| Amgen Inc | 9.48% | 13.08% | 89.32% |
| Pfizer Inc | 2.12% | 2.53% | 4.91% |
| Bristol myers Squibb Company | 10.27% | 13.58% | 46.65% |
Sign in to see all peers for Sonnet Biotherapeutics Holdings Inc .
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Sonnet Biotherapeutics Holdings Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Sonnet Biotherapeutics Holdings Inc | - | 14.87 |
| Novartis Ag | 20.53 | 5.07 |
| Astrazeneca Plc | 25.38 | 4.42 |
| Amgen Inc | 25.97 | 5.97 |
| Pfizer Inc | 37.66 | 2.57 |
| Bristol myers Squibb Company | 14.06 | 2.66 |
| PEERS AVERAGE | 27.00 | 4.30 |
Sign in to see all peers for Sonnet Biotherapeutics Holdings Inc .
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.